​

Innoviva (INVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

INVA Stock Forecast

Innoviva (INVA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $32.50, with a high of $46.00 and a low of $17.00. This represents a 47.93% increase from the last price of $21.97.

$15 $22 $29 $36 $43 $50 High: $46 Avg: $32.5 Low: $17 Last Closed Price: $21.97

INVA Stock Rating

Innoviva stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (50.00%), 4 Hold (40.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 4 5 Strong Sell Sell Hold Buy Strong Buy

INVA Price Target Upside V Benchmarks

TypeNameUpside
StockInnoviva47.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts235
Avg Price Target$33.50$37.67$33.00
Last Closing Price$21.97$21.97$21.97
Upside/Downside52.48%71.46%50.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-4-1-5
Feb, 26-3-1-4
Jan, 26-3-1-4
Dec, 25-3-1-4
Nov, 2522-1-5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Steve SeedhouseCantor Fitzgerald$32.00$23.9833.44%45.65%
Feb 17, 2026BTIG$35.00$22.7054.19%59.31%
Dec 16, 2025H.C. Wainwright$46.00$20.15128.29%109.38%
Sep 30, 2025Goldman Sachs$17.00$19.03-10.67%-22.62%
Aug 11, 2025Trevor AllredOppenheimer$35.00$19.9375.61%59.31%
Mar 07, 2025Scotiabank$55.00$17.64211.79%150.34%
Aug 08, 2022Morgan Stanley$13.00$14.72-11.68%-40.83%
Jul 15, 2022Morgan Stanley$12.00$14.37-16.49%-45.38%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 17, 2026BTIGBuyinitialise
Dec 16, 2025H.C. WainwrightBuyBuyhold
Sep 30, 2025Goldman SachsSellinitialise
Aug 11, 2025Seaport GlobalBuyinitialise
Aug 11, 2025OppenheimerOutperforminitialise
Jul 14, 2025H.C. WainwrightBuyinitialise
Mar 07, 2025ScotiabankOutperforminitialise
Jun 18, 2024Cantor FitzgeraldOverweightinitialise
Aug 08, 2022Morgan StanleyUnderweightUnderweighthold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.24$3.07$2.92$0.37$4.02---
Avg Forecast$2.02$3.72$1.67$0.43$1.72$1.78$2.15$2.78
High Forecast$2.08$3.85$1.67$0.43$1.72$1.78$2.15$2.78
Low Forecast$1.96$3.58$1.67$0.43$1.72$1.78$2.15$2.78
Surprise %60.40%-17.47%74.85%-13.95%133.72%---

Revenue Forecast

$250M $300M $350M $400M $450M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$391.87M$331.34M$310.46M$358.71M$411.33M---
Avg Forecast$292.18M$337.53M$300.14M$353.70M$353.05M$377.95M$407.00M$482.60M
High Forecast$299.08M$346.72M$300.14M$353.70M$353.05M$384.57M$407.00M$482.60M
Low Forecast$285.28M$328.33M$300.14M$353.70M$353.05M$371.32M$407.00M$482.60M
Surprise %34.12%-1.83%3.44%1.42%16.51%---

Net Income Forecast

$0 $60M $120M $180M $240M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$265.85M$213.92M$179.72M$23.39M$271.17M---
Avg Forecast$72.87M$93.40M$113.26M$36.92M$148.99M$154.64M$186.78M$241.52M
High Forecast$75.11M$112.07M$135.91M$36.92M$148.99M$154.64M$186.78M$241.52M
Low Forecast$70.64M$74.72M$90.61M$36.92M$148.99M$154.64M$186.78M$241.52M
Surprise %264.82%129.05%58.68%-36.65%82.00%---

INVA Forecast FAQ

Is Innoviva stock a buy?

Innoviva stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Innoviva is a favorable investment for most analysts.

What is Innoviva's price target?

Innoviva's price target, set by 10 Wall Street analysts, averages $32.5 over the next 12 months. The price target range spans from $17 at the low end to $46 at the high end, suggesting a potential 47.93% change from the previous closing price of $21.97.

How does Innoviva stock forecast compare to its benchmarks?

Innoviva's stock forecast shows a 47.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Innoviva over the past three months?

  • March 2026: 0% Strong Buy, 80.00% Buy, 0% Hold, 20.00% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 75.00% Buy, 0% Hold, 25.00% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 75.00% Buy, 0% Hold, 25.00% Sell, 0% Strong Sell.

What is Innoviva’s EPS forecast?

Innoviva's average annual EPS forecast for its fiscal year ending in December 2026 is $1.78, marking a -55.72% decrease from the reported $4.02 in 2025. Estimates for the following years are $2.15 in 2027, and $2.78 in 2028.

What is Innoviva’s revenue forecast?

Innoviva's average annual revenue forecast for its fiscal year ending in December 2026 is $377.95M, reflecting a -8.12% decrease from the reported $411.33M in 2025. The forecast for 2027 is $407M, and $482.6M for 2028.

What is Innoviva’s net income forecast?

Innoviva's net income forecast for the fiscal year ending in December 2026 stands at $154.64M, representing a -42.97% decrease from the reported $271.16M in 2025. Projections indicate $186.78M in 2027, and $241.52M in 2028.